These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38786974)

  • 1. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
    Rehman WU; Yarkoni M; Ilyas MA; Athar F; Javaid M; Ehsan M; Khalid MT; Pasha A; Selma AB; Yarkoni A; Patel K; Sabouni MA; Rehman AU
    J Cardiovasc Dev Dis; 2024 May; 11(5):. PubMed ID: 38786974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Taheri H; Filion KB; Windle SB; Reynier P; Eisenberg MJ
    Cardiology; 2020; 145(4):236-250. PubMed ID: 32172237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based mechanism and inhibition of cholesteryl ester transfer protein.
    Xue H; Zhang M; Liu J; Wang J; Ren G
    Curr Atheroscler Rep; 2023 Apr; 25(4):155-166. PubMed ID: 36881278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
    Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
    Nurmohamed NS; Ditmarsch M; Kastelein JJP
    Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
    Mohammadpour AH; Akhlaghi F
    Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein inhibitors in precision medicine.
    Su X; Li G; Deng Y; Chang D
    Clin Chim Acta; 2020 Nov; 510():733-740. PubMed ID: 32941836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
    Nelson AJ; Sniderman AD; Ditmarsch M; Dicklin MR; Nicholls SJ; Davidson MH; Kastelein JJP
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
    Kastelein JJP; Hsieh A; Dicklin MR; Ditmarsch M; Davidson MH
    Curr Atheroscler Rep; 2024 Feb; 26(2):35-44. PubMed ID: 38133847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?
    Doggrell SA
    Expert Opin Pharmacother; 2018 Apr; 19(6):611-615. PubMed ID: 29498299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
    Mabuchi H; Nohara A; Inazu A
    Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
    Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
    Ferri N; Corsini A; Sirtori CR; Ruscica M
    Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the mechanisms of cholesteryl ester transfer protein inhibitors.
    Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Dec; 1862(12):1606-1617. PubMed ID: 28911944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.